Hold - Price 66.98 on Feb. 5 by McAdams Wright Ragen We expect COST to report January comparable-store sales in the 6% to 7% range [versus] comparatively easy 2% prior-year. We expect that January comps benefited from a weak dollar versus Canadian and British currencies....Gas inflation was undoubtedly a benefit as well. Our 70 target equates to 23 times our fiscal-year '08 estimate. Market-cap: $29 billion.

Hold - Price 26.53 on Feb. 6 by Wedbush Morgan Target: 25. We see 2008 as transition[al] for Diebold, as it completes its accounting reviews and proceeds with an extensive restructuring effort; 2007 revenue of $2.95 billion ($31 million positive impact from review) was above our and consensus estimate, $2.87 billion....We expect DBD to provide preliminary '07 earnings-per-share results by April. Market-cap. $1.8 billion

Buy - Price 4.25 on Feb. 5 by Sterne, Agee & Leach The 10 target [is] 14.9 and 1.9 times our '08 estimates of EPS and Ebitda, respectively. EXXI currently sells for 6.3 and 0.8 times our estimates of 2008 EPS and earnings before interest, taxes, depreciation and amortization, versus 12.7 and 3.9 times the group averages, respectively, a discount....Energy XXI...acquires/exploits producing oil and gas reserves. Market-cap: $376 million.

Buy - Price 6.42 on Feb. 5 by Signal Hill Entropic reported $40.2 million in revenue and five cents non-GAAP EPS, soundly beating our and Street estimates on higher revenues, margin and contribution from other income. We...believe ENTR is well-positioned to take advantage of [many] positive developments in transmission of video within home networks. Market-cap: $437 million.

Strong Buy - Price 41.33 on Feb. 5 by JMP Securities Molecular diagnostic (MDx) revenue, $53.1 million, [was] above our $51.1 million and consensus $50 million -- a 15% increase from last quarter and 55%-plus year over year. Myriad increased gross profit margin to 86%, up from last quarter's 84%....Net loss of 11 cents a share was in line with our estimate....We're increasing our FY08 total revenues from $220.9 million to $232.9 million and decreasing our FY08 net loss from 30 cents to 29 cents. MYGN plans to report top-line data from Phase III trial of Flurizan on Alzheimer's disease in June....Our 75 target is based on sum-of-the-parts analysis for the MDx business of $65 and $10 for Flurizan. Market-cap: $1.8 billion.

Outperform - Price 21.15 on Feb. 5 by Cowen & Co. [Telecommunications firm] Savvis' expansion remains on track. We look for substantial outperformance as Ebitda accelerates throughout the year. SVVS management reported seeing no signs of demand weakness related to the slowing economy....Trading at only 7.7 times '08 estimated Ebitda, current level [appears to be] an excellent entry opportunity. Our [discounted cash flow] indicates 70% outperformance potential versus the market over the next 12 months, implying 9.3 times 2009E Ebitda. Market-cap: $1.2 billion

Buy - Price 66.25 on Feb. 5 by Zacks Research The aerospace industry is entering the sweet spotof this cycle. TGI [an aircraft-components designer, manufacturer and distributor] reported net sales from continuing operations for 3Q of fiscal year ending March 31 at $275.1 million, versus $237.8 million for [the year-ago period]....we believe TGI is [currently] undervalued and upgrade to Buy. Market-cap: $915 million.

Market Perform - Price 37.15 on Feb. 6 by Morgan Keegan [Financial-services and insurance firm] Unitrin reported an operating loss for Q407 of 3 cents a share, versus an 88-cent gain in Q406 -- materially below our estimate of 58 cents....The loss...was driven primarily by a significant addition to Fireside Bank's loan-loss reserves. Fireside lends money to customers with subprime credit ratings to facilitate the purchase of used automobiles. [Unitirin] repurchased 516,000 of its own shares during the quarter. Market-cap: $2.4 billion.